Generics boost Glenmark's revenues in first quarter
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticalshas reported a 29.8% increase in consolidated revenues to Rs4.66 billion ($112.1 million) for its first quarter ended June 30th, led by strong growth in the generics business. Consolidated net profits increased to Rs1.15 billion (+102%).